| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8ad230702e175c65a4cb382bc625436 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1658
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2022-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc1db42efa921e5512ca8cc4f21be948
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ff111ff981fb8b18ef7006152ac7c1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1df9927c4ddfc068e4a9cc2c1b22765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_106ea7b3ac1d67dd77288630f0157149 |
| publicationDate |
2022-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022258625-A1 |
| titleOfInvention |
Co-amorphous forms for use in cancer therapy |
| abstract |
The invention relates to a co-amorphous form of beta-lactoglobulin and a drug substance selected from olaparib and abiraterone acetate, wherein the concentration of the drug substance in the co-amorphous form is from 10% to 90% w/w based on the total weight of the co-amorphous form. I also related to compositions comprising a co-amorphous form, and a dosage regime for the treatment of cancer such as prostate cancer, notably castration-resistant prostate cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023094538-A1 |
| priorityDate |
2021-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |